251 related articles for article (PubMed ID: 28339199)
1. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
[TBL] [Abstract][Full Text] [Related]
2. Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.
Kaski SW; White AN; Gross JD; Siderovski DP
Anesth Analg; 2021 Feb; 132(2):406-419. PubMed ID: 33332902
[TBL] [Abstract][Full Text] [Related]
3. Molecular Interaction Between Butorphanol and κ-Opioid Receptor.
Ji J; Lin W; Vrudhula A; Xi J; Yeliseev A; Grothusen JR; Bu W; Liu R
Anesth Analg; 2020 Sep; 131(3):935-942. PubMed ID: 32701545
[TBL] [Abstract][Full Text] [Related]
4. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel functionally selective κ-opioid receptor scaffolds.
White KL; Scopton AP; Rives ML; Bikbulatov RV; Polepally PR; Brown PJ; Kenakin T; Javitch JA; Zjawiony JK; Roth BL
Mol Pharmacol; 2014 Jan; 85(1):83-90. PubMed ID: 24113749
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Assessment of Fused β-Carboline Derivatives as Kappa Opioid Receptor Agonists.
Yadav VD; Kumar L; Kumari P; Kumar S; Singh M; Siddiqi MI; Yadav PN; Batra S
ChemMedChem; 2021 Jun; 16(12):1917-1926. PubMed ID: 33599108
[TBL] [Abstract][Full Text] [Related]
7. Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.
Schmitt S; Colloc'h N; Perrio C
Eur J Med Chem; 2015 Jan; 90():742-50. PubMed ID: 25513968
[TBL] [Abstract][Full Text] [Related]
8. Chemotype-selective modes of action of κ-opioid receptor agonists.
Vardy E; Mosier PD; Frankowski KJ; Wu H; Katritch V; Westkaemper RB; Aubé J; Stevens RC; Roth BL
J Biol Chem; 2013 Nov; 288(48):34470-83. PubMed ID: 24121503
[TBL] [Abstract][Full Text] [Related]
9. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
11. Modulation of serotonin transporter function by kappa-opioid receptor ligands.
Sundaramurthy S; Annamalai B; Samuvel DJ; Shippenberg TS; Jayanthi LD; Ramamoorthy S
Neuropharmacology; 2017 Feb; 113(Pt A):281-292. PubMed ID: 27743931
[TBL] [Abstract][Full Text] [Related]
12. 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.
Rives ML; Rossillo M; Liu-Chen LY; Javitch JA
J Biol Chem; 2012 Aug; 287(32):27050-4. PubMed ID: 22736766
[TBL] [Abstract][Full Text] [Related]
13. Structure-Activity Relationships of [des-Arg
Ramos-Colon CN; Lee YS; Remesic M; Hall SM; LaVigne J; Davis P; Sandweiss AJ; McIntosh MI; Hanson J; Largent-Milnes TM; Vanderah TW; Streicher J; Porreca F; Hruby VJ
J Med Chem; 2016 Nov; 59(22):10291-10298. PubMed ID: 27797517
[TBL] [Abstract][Full Text] [Related]
14. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse.
Khan MIH; Sawyer BJ; Akins NS; Le HV
Eur J Med Chem; 2022 Dec; 243():114785. PubMed ID: 36179400
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of N-hydroxy-aminobenzyloxyarylamide analogues as novel selective κ opioid receptor antagonists.
He G; Song Q; Wang J; Xu A; Peng K; Zhu Q; Xu Y
Bioorg Med Chem Lett; 2020 Jul; 30(13):127236. PubMed ID: 32386980
[TBL] [Abstract][Full Text] [Related]
16. Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy.
Schrader TO; Lorrain KI; Bagnol D; Edu GC; Broadhead A; Baccei C; Poon MM; Stebbins KJ; Xiong Y; Lorenzana AO; Chan JR; Green AJ; Lorrain DS; Chen A
ACS Chem Neurosci; 2024 Feb; 15(3):685-698. PubMed ID: 38265210
[TBL] [Abstract][Full Text] [Related]
17. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
18. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.
Schmidhammer H; Erli F; Guerrieri E; Spetea M
Molecules; 2020 Nov; 25(21):. PubMed ID: 33147885
[TBL] [Abstract][Full Text] [Related]
19. κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.
Abraham AD; Fontaine HM; Song AJ; Andrews MM; Baird MA; Kieffer BL; Land BB; Chavkin C
Neuropsychopharmacology; 2018 Jan; 43(2):362-372. PubMed ID: 28649993
[TBL] [Abstract][Full Text] [Related]
20. Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses.
Dunn AD; Reed B; Erazo J; Ben-Ezra A; Kreek MJ
ACS Chem Neurosci; 2019 Aug; 10(8):3590-3600. PubMed ID: 31313902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
